Moderna Sees Single-Dose COVID-19 Vaccine Launch In India In 2022 - Johnson & Johnson (NYSE:JNJ), Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

Moderna Inc MRNA expects to launch a single-dose COVID-19 vaccine in India in 2022 and is in talks with Cipla, among other Indian firms, reports Economic Times.
While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021.
Also, Johnson & Johnson JNJ has limited prospects to export its COVID-19 vaccine outside the U.S., according to undisclosed sources.
Cipla has already evinced interest in procuring 50 million doses from Moderna for 2022 and has requested confirmation from the central government.
Today, Moderna said that its vaccine is effective for 12 to 17 year-olds; it will seek FDA approval.
Meanwhile, Pfizer Inc PFE is ready to offer 50 million shots in 2021, but it wants significant regulatory relaxations, including indemnification.
The company has indicated availability of 50 million vaccine doses — 10 million each in July and August, 20 million in September, and 10 million in October.
However, Pfizer said it would deal only with the Government of India, and payment for vaccines will have to be made by GOI to Pfizer India.
Price Action: MRNA shares are up 2.8% at $168.75 during the market session on the last check Tuesday.